Canaccord Genuity Reiterates Buy Rating on Neurocrine Bio. (NBIX)

February 12, 2026 7:26 AM EST Send to a Friend
Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating and $164.00 price target on Neurocrine Bio. (NASDAQ: NBIX).The analyst commented ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login